-
Shanghai Pharmaceuticals Partners with HKSTP and Shanghai Biomedicine Fund on R&D Collaboration
•
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), a leading Chinese pharmaceutical company, has entered into a memorandum of understanding to collaborate with Hong Kong Science & Technology Park (HKSTP) and Shanghai Biomedicine Fund, a RMB 50 billion (USD 11.44 billion) municipal industry fund approved by the Shanghai government and initiated by…
-
Zhongsheng Pharmaceutical Completes Phase I Study of RAY1216 for COVID-19 Treatment
•
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the completion of subject enrollment and clinical observation for the Phase I clinical study of RAY1216, an innovative oral therapy for the novel coronavirus developed by its subsidiary Guangdong Raynovent Biotech Co., Ltd. The study results demonstrated good safety and pharmacokinetic…
-
CSPC Pharmaceutical’s rhTNK-tPA Meets Primary Endpoint in Stroke Study
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the Phase III clinical study for its recombinant human TNK tissue-type plasminogen activator for injection (rhTNK-tPA) in acute ischemic stroke has reached the pre-set primary endpoint. Study DetailsThe multi-center, prospective, randomized, open, blinded, non-inferiority Phase III clinical study was designed to…
-
HeNan Genuine Biotech Files for IPO to Fund Azvudine Commercialization
•
China-based HeNan Genuine Biotech Co., Ltd has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange (HKSE). The proceeds from the IPO will be used for the manufacturing and commercialization of its COVID-19 therapy azvudine, as well as the clinical development of drugs for HIV infection,…
-
Innovent Biologics’ Q2 2022 Revenues Surpass RMB 1 Billion, Seven Products Approved
•
Innovent Biologics Inc. (HKG: 1801) released its Q2 2022 financial report, with product revenues exceeding RMB 1 billion (USD 148.2 million). The company has obtained marketing approvals for seven products to date, including PD-1 inhibitor Tyvyt (sintilimab), Byvasda (bevacizumab), a biosimilar version of Avastin, Sulinno, autoimmune disease drug Humira (adalimumab),…
-
Hybio Pharmaceutical’s HY3000 Nasal Spray for COVID-19 Enters NMPA Review
•
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that its clinical trial filing for HY3000 nasal spray, a Category 1 chemical drug targeting COVID-19, has been accepted for review by the National Medical Products Administration (NMPA). Drug DetailsHY3000 is a novel polypeptide membrane fusion inhibitor that binds to the HR1…
-
GenScript’s Legend Biotech Appoints Three New Directors to Board
•
Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary Legend Biotech Corporation (NASDAQ: LEGN) has appointed Dr. Fangliang Zhang, Dr. Li Mao, and Mr. Tomas J. Heyman to the Company’s Board of Directors, effective as of August 2, 2022. Dr. Zhang, Dr. Mao, and…
-
Boehringer Ingelheim Wins Patent Infringement Ruling Against HEC Over Trajenta
•
The China National Intellectual Property Administration (CNIPA) has ruled in favor of German pharmaceutical giant Boehringer Ingelheim (BI) in a patent infringement dispute with HEC and its affiliate Yichang HEC Changjiang Pharmaceutical Co., Ltd. The ruling centers on BI’s patent protecting the linagliptin compound used in its Trajenta diabetes drug.…
-
Zelgen’s Jacktinib Hits Phase IIb Endpoint in Myelofibrosis Study
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the successful completion of a pivotal Phase IIb clinical trial (ZGJAK006) for its in-house Janus kinase (JAK) inhibitor, jacktinib, in patients with ruxolitinib-intolerant, medium- to high-risk myelofibrosis. The study met its primary endpoint, with 43.2% of subjects achieving ≥35% spleen volume reduction…
-
Wision A.I.’s Polyp Detection Software Secures NMPA Approval for Colonoscopy Use
•
The National Medical Products Administration (NMPA) has approved China-based Wision A.I.’s intestinal polyp electronic colonoscopy image-assisted detection software for marketing in China. The software marks the country’s first deep learning – powered tool designed to aid in polyp detection during endoscopic procedures. Product FeaturesThe software integrates with specified electronic colonoscopes,…
-
Ethicon’s Hemostatic Granules Win NMPA Approval for Endoscopic Surgery Use
•
The National Medical Products Administration (NMPA) has granted marketing approval to U.S. medical device firm Ethicon LLC for its absorbable regenerated oxidized cellulose hemostatic granules, designated as an innovative product. The approval marks a milestone for Ethicon’s hemostatic portfolio in China’s surgical device market. Product DetailsThe approved product comprises two…
-
Bloomage Biotech Terminates Medytox Pact Over Botox Supply Issues
•
China-based Bloomage Biotech (SHA: 688363) announced that its wholly owned subsidiary, Gentix Limited, has issued a lawyer’s letter to South Korea-headquartered Medytox Inc. on July 29, 2022, seeking to terminate the agreement between the two companies related to Botox and other medical aesthetics products. The move comes after no products…
-
WuXi Biologics Partners with AstraZeneca for Local Production of Evusheld
•
China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced a strategic partnership with UK pharmaceutical giant AstraZeneca for the local manufacturing of Evusheld (tixagevimab, cilgavimab), a COVID-19 prophylactic neutralizing antibody combination. Financial details of the partnership were not disclosed. Drug ApprovalsEvusheld received Emergency Use…
-
Structure Therapeutics Oversubscribes USD33m on Top of USD100m Series B Round
•
Structure Therapeutics, a Sino-US firm formerly known as ShouTi Inc., announced the oversubscription of USD33 million on top of a USD100 million Series B financing round in October last year. The expanded funding included new investors such as Deep Track Capital and Piper Heartland Healthcare Capital. Proceeds will support key…
-
Ascletis Pharma’s ASC10 Receives IND Approval for COVID-19 Treatment in US and China
•
China-based Ascletis Pharma Inc. (HKG: 1672) has provided updates on the clinical progress of ASC10, its oral RNA-dependent RNA polymerase (RdRp) drug therapy for COVID-19. The National Medical Products Administration (NMPA) has accepted an Investigational New Drug (IND) filing for review, and the US Food and Drug Administration (FDA) has…
-
ProfoundBio Receives FDA Approval for PRO1184, Appoints New CMO
•
China-based macromolecular targeted therapy developer ProfoundBio (Suzhou) Co., Ltd announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its antibody drug conjugate (ADC) PRO1184 in advanced tumors. The announcement was made alongside the appointment of Dr. Naomi Hunder as the company’s chief…
-
AstraZeneca’s H1 2022 Revenues Surge 48%, Led by Oncology and Vaccines
•
UK-based AstraZeneca (AZ, NASDAQ: AZN) released its financial report for H1 2022, showing a 48% year-on-year (YOY) increase in total global revenues to USD22.16 billion in constant currency terms. The company saw strong growth across various disease areas and key products. Business Performance Key Products COVID-19 Portfolio Geographical Performance Challenges…
-
Lee’s Pharma Completes Enrollment for NVK-002 Myopia Trials in China
•
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced the completion of patient enrollment in two Phase III trials for NVK-002, its core product for controlling myopia progression in children and adolescents. The studies, known as China CHAMP and Small CHAMP, mark a key milestone in…
-
Lynk Pharma Gets NMPA Green Light for LNK01004 Atopic Dermatitis Study
•
Hangzhou-based Lynk Pharmaceuticals Co., Ltd announced it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study of its drug LNK01004 for atopic dermatitis (AD). The drug was previously approved for a clinical trial in mild to moderate plaque psoriasis, with the first patient dosed…
-
Sciwind Biosciences’ XW003 Hits Phase II Trial Goals in Type 2 Diabetes Treatment
•
Hangzhou-based biopharma Sciwind Biosciences Co., Ltd announced positive results from a 20-week Phase II trial of its XW003 (ecnoglutide) in Chinese adults with type 2 diabetes (T2D). The study demonstrated the drug’s safety, tolerability, and significant HbA1c reductions, meeting primary endpoints. Study DetailsThe multi-center, randomized, placebo-controlled trial involved 145 patients…
